Long COVID’s brain fog finally has a biological explanation: Dopamine loss

A University of Toronto/CAMH PET-imaging study of 24 long-COVID patients versus 24 controls found 16%-20% lower VMAT2 dopamine-nerve-terminal markers in striatal brain regions linked to motivation, memory and movement. The biomarker reductions closely tracked symptoms, potentially providing an objective biological basis for long COVID and supporting targeted treatment development. Researchers are preparing a clinical trial repurposing a brain-penetrant dopamine-related drug, although funding proposals have missed two rounds and reversibility remains uncertain.

Analysis

This is not yet a monetizable diagnostic catalyst: PET-based VMAT2 measurement is expensive, capacity-constrained, and impractical for broad screening. The investable implication is instead a gradual de-risking of long-COVID as a biologically defined indication, which can expand trial enrollment, improve endpoint selection, and eventually support reimbursement for targeted therapies. Near term, this favors PET-radiotracer and neuroimaging infrastructure only marginally; the addressable incremental scan volume is too small to move earnings for Siemens Healthineers (SEMHF) or GE HealthCare (GEHC).

The more relevant 6-18 month opportunity is in companies with CNS, neuroinflammation, or dopamine-pathway assets that can credibly repurpose existing molecules. A defined biomarker could separate patients with persistent inflammatory injury from those recovering spontaneously, reducing placebo noise—a major source of value creation in CNS development. However, the cited evidence is a 48-person observational study, so it does not establish causality, reversibility, or that changing dopamine signaling improves functional outcomes; investors should not capitalize prospective long-COVID revenue until a controlled trial reports objective and patient-function endpoints.

Contrarian view: the strongest implication may be negative for indiscriminate stimulant or dopamine-agonist narratives. If the underlying issue is loss of terminals rather than temporarily suppressed neurotransmitter release, symptomatic dopamine enhancement may have limited durability and could carry tolerability risk. The likely commercial winners are therefore therapies that demonstrate both neuroinflammation control and functional recovery, not merely improved fatigue scores; this raises the evidentiary bar but creates a potentially defensible niche if successful.

Key Decisions for Investors

• No immediate directional trade: the study is underpowered and lacks a publicly identified drug, trial sponsor, or regulatory pathway; treat any near-term biotech price move tied to this report as unsupported.
• Create a 1-3 month watchlist around CNS repurposing and neuroinflammation developers, including Denali Therapeutics (DNLI), Biogen (BIIB), and Roche (RHHBY). Act only after a registered controlled long-COVID study identifies the agent, biomarker-enrichment strategy, and functional primary endpoint.
• Use GEHC and SEMHF only as low-beta monitoring proxies rather than long catalysts. A trade becomes actionable only if hospital systems or payers adopt a scalable diagnostic workflow beyond research PET; absent that, incremental imaging revenue is immaterial.
• For any future long-COVID therapeutic long, require evidence of improvement in objective cognitive/motor measures plus durable patient-reported function at 12-24 weeks. Falsify on failure to replicate the biomarker in a larger cohort, lack of correlation with functional outcomes, or trial discontinuation from funding constraints.